Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Tax Provisions: 2023-2025

Historic Tax Provisions for Entrada Therapeutics (TRDA) over the last 2 years, with Sep 2025 value amounting to $700,000.

  • Entrada Therapeutics' Tax Provisions rose 136.84% to $700,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year decrease of 113.18%. This contributed to the annual value of $900,000 for FY2024, which is 95.20% down from last year.
  • Latest data reveals that Entrada Therapeutics reported Tax Provisions of $700,000 as of Q3 2025, which was up 250.00% from $200,000 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Tax Provisions registered a high of $18.7 million during Q4 2023, and its lowest value of -$17.4 million during Q3 2023.
  • In the last 3 years, Entrada Therapeutics' Tax Provisions had a median value of $1.3 million in 2024 and averaged $2.1 million.
  • In the last 5 years, Entrada Therapeutics' Tax Provisions plummeted by 109.76% in 2024 and then skyrocketed by 136.84% in 2025.
  • Over the past 3 years, Entrada Therapeutics' Tax Provisions (Quarterly) stood at $18.7 million in 2023, then crashed by 109.76% to -$1.8 million in 2024, then spiked by 136.84% to $700,000 in 2025.
  • Its last three reported values are $700,000 in Q3 2025, $200,000 for Q2 2025, and -$1.8 million during Q4 2024.